Tuesday 17 November 2026 Sign in / SubscribeFree daily emailMarket analysisEnterpriseVigiEye regulatory newsCompePharma CRM & HR →
The business of pharma
Opinion · CompePharma View

A guidance raise is only as good as who controls the trigger

Q3 guidance moves look alike on a headline but differ in what they say about control. The companies that own their drivers have earned more trust than those waiting on a partner's calendar.

15 Nov 2026 · CompePharma editorial

Same word, different promise

Read this quarter's headlines quickly and you would think the industry is in a raising mood. Eton lifted 2026 revenue guidance to more than $175 million from more than $145 million, and its Adjusted EBITDA target to more than 40% from more than 35%. Novavax raised full-year Non-GAAP Adjusted Total Revenue by $145 million, to $400 million at the mid-point. Ionis, by contrast, lowered 2026 product sales guidance for Tryngolza. It still reaffirmed total revenue, operating loss and cash guidance.

My argument is that the direction of a guidance change matters less than who holds the trigger. Guidance built on a company's own commercial execution is a different kind of statement from guidance that depends on someone else's decision. Leaders and boards should price the two differently.

Subscribe to keep reading

$4.99 / month

  • Every article, analysis and opinion piece on CompePharma and VigiEye
  • One subscription for both sites, cancel any time

Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.

We'll email you a link to confirm your address, then take you to secure checkout (Stripe). Billed monthly until you cancel; access starts at once, so the 14-day withdrawal right ends when it does. Already a subscriber? Enter your email and the link will sign you in. See our terms and privacy policy.

Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. It can contain errors; check the sources. Not investment advice.

More Opinion · CompePharma ViewAll →